Experimental cancer drug BR105 tested in 31 patients – study halted early
NCT ID NCT05351697
First seen Nov 21, 2025 · Last updated May 14, 2026 · Updated 26 times
Summary
This early-stage study tested an experimental drug called BR105 in 31 adults with advanced cancers that no longer responded to standard treatments. The main goals were to check the drug's safety, find the best dose, and see if it could shrink tumors. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100000, China
Conditions
Explore the condition pages connected to this study.